Epidermal growth factor receptor inhibitors
Epidermal growth factor receptor inhibitors, abbreviated EGFR inhibitors, is a class of drugs that blocks the EGF receptor.
Drugs
- Gefitinib (Iressa).[1]
- Erlotinib (Tarceva).[1]
- Afatinib (Gilotrif) - esp. effective when del19 is present.[2]
Note:
- Both gefitinib and erlotinib are also classified as tyrosine kinase inhibitors (TKIs).
Use
References
- ↑ 1.0 1.1 Sun Y, Ren Y, Fang Z, et al. (October 2010). "Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases". J. Clin. Oncol. 28 (30): 4616–20. doi:10.1200/JCO.2010.29.6038. PMID 20855837.
- ↑ Yang, JC.; Wu, YL.; Schuler, M.; Sebastian, M.; Popat, S.; Yamamoto, N.; Zhou, C.; Hu, CP. et al. (Feb 2015). "Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.". Lancet Oncol 16 (2): 141-51. doi:10.1016/S1470-2045(14)71173-8. PMID 25589191.